Singular Genomics Systems (OMIC) Investor Presentation summary

Company overview and financials

• Employs approximately 195 people and holds around 300 issued and pending patents.

• Raised $450M in capital with $133M in cash as of June 30, 2024.

• Listed on NASDAQ under the ticker OMIC.

Product platforms and technology

• G4 platform offers fast, flexible, and scalable next-generation sequencing (NGS) with industry-leading run times and high data output.

• G4X platform, in early access for 2024, is designed for high-throughput in situ spatial sequencing, enabling multiomic data from a single sample.

• Both platforms are for research use only and not for diagnostic procedures.

Market opportunity and growth drivers

• NGS market projected to grow from $7B in 2023 to $20B by 2030, driven by clinical and oncology applications.

• Spatial sequencing market expected to expand from $2B in 2023 to $11B by 2030, fueled by advances in spatial biology and multiomics.

• G4 and G4X platforms target unmet needs in throughput, cost, and data quality for these fast-growing markets.